Non-CNS Cell Types
The University of Sao Paulo group completed both Phase 1 and 2 studies of autologous bone marrow stem cells in RP, delivered by intravitreal injection. The date of completion is listed as 2013. A safety study at Mahidol University in Thailand using intravitreal bone marrow-derived mesenchymal stem cells in RP is listed as “enrolling by invitation” and was due to finish in 2014.
A pilot safety study using autologous bone marrow-derived CD34+ hematopoietic stem cells was initiated at the University of California, Davis in 2012. The cells are injected intravitreally in RP, AMD, and a range of retinopathies. The study is listed as “enrolling by invitation” with estimated completion in 2017. Another study with intravitreal injection of autologous bone-marrow derived stem cells is being performed by Red de Terapia Celular in Murcia, Spain. This study includes a subconjunctival placebo control in the fellow eye and is due to be completed later this year, according to entries on clinicaltrials.gov. Another trial using autologous bone marrow cells by Stem Cells Arabia is underway in Amman, Jordan, another at Chaitanya Hospital, Pune, India, and another in Florida and Dubai by MD Stem Cells.
In addition, Janssen is testing their umbilical tissue-derived cells subretinally in a Phase 1/2a study in dry AMD, with fellow eye controls. The study is listed as “ongoing but not recruiting participants.” A prior study in RP was terminated.